Syndax Pharmaceuticals, Inc. (SNDX)
20.04
+0.75
(+3.89%)
USD |
NASDAQ |
Sep 01, 14:59
Syndax Pharmaceuticals Cash and Short Term Investments (Quarterly) : 547.86M for June 30, 2026
Cash and Short Term Investments (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 547.86M |
| March 31, 2026 | 352.06M |
| December 31, 2025 | 394.07M |
| September 30, 2025 | 435.98M |
| June 30, 2025 | 455.23M |
| March 31, 2025 | 512.20M |
| December 31, 2024 | 572.88M |
| September 30, 2024 | 389.61M |
| June 30, 2024 | 425.10M |
| March 31, 2024 | 434.58M |
| December 31, 2023 | 570.70M |
| September 30, 2023 | 363.56M |
| June 30, 2023 | 398.80M |
| March 31, 2023 | 432.39M |
| December 31, 2022 | 475.80M |
| September 30, 2022 | 337.95M |
| June 30, 2022 | 366.91M |
| March 31, 2022 | 398.04M |
| December 31, 2021 | 440.05M |
| September 30, 2021 | 229.83M |
| June 30, 2021 | 253.25M |
| March 31, 2021 | 271.34M |
| December 31, 2020 | 293.18M |
| September 30, 2020 | 170.27M |
| June 30, 2020 | 186.87M |
| Date | Value |
|---|---|
| March 31, 2020 | 99.12M |
| December 31, 2019 | 59.78M |
| September 30, 2019 | 72.34M |
| June 30, 2019 | 80.62M |
| March 31, 2019 | 92.84M |
| December 31, 2018 | 81.01M |
| September 30, 2018 | 89.70M |
| June 30, 2018 | 98.49M |
| March 31, 2018 | 113.32M |
| December 31, 2017 | 130.08M |
| September 30, 2017 | 120.69M |
| June 30, 2017 | 130.06M |
| March 31, 2017 | 92.89M |
| December 31, 2016 | 105.48M |
| September 30, 2016 | 115.72M |
| June 30, 2016 | 125.51M |
| March 31, 2016 | 133.72M |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | 11.74M |
| June 30, 2014 | 5.061M |
| March 31, 2014 | 9.548M |
Cash and Short Term Investments Definition
Represents the sum of cash and short term investments.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash and Short Term Investments (Quarterly) Benchmarks
| Viking Therapeutics, Inc. | 501.66M |
| Kura Oncology, Inc. | 519.02M |
| ACADIA Pharmaceuticals, Inc. | 956.47M |
| Alnylam Pharmaceuticals, Inc. | 3.308B |
| Anika Therapeutics, Inc. | 38.41M |